Canurta Therapeutics
Develops multi-target botanical therapies with AI-backed discovery for inflammation and neurological diseases.
Website: https://www.canurta.com/
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Canurta Therapeutics |
| Tagline | Develops multi-target botanical therapies with AI-backed discovery for inflammation and neurological diseases. |
| Headquarters | Brampton, Ontario, Canada |
| Founded | 2021 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | $10M+ |
| Total Disclosed | ~$13,000,000 |
Links
PUBLIC
- Website: https://www.canurta.com/
- LinkedIn: https://ca.linkedin.com/company/canurta
- LinkedIn (Founder): https://www.linkedin.com/in/akeemgardner/
- Crunchbase: https://www.crunchbase.com/organization/canurta-therapeutics
- PitchBook: https://pitchbook.com/profiles/company/503587-81
Executive Summary
PUBLIC
Canurta Therapeutics is a Brampton, Ontario pre-clinical biotech building multi-target botanical drugs from rare hemp-derived polyphenols, with an AI-assisted discovery platform and a lead candidate, CNR-401, positioned for first-in-human ALS trials in 2025 [Canurta.com, 2025] [Crunchbase]. The company was founded in 2021 by Akeem Gardner, a Brampton-born entrepreneur who pivoted from a hemp-cultivation venture into therapeutics after partnering with academic researchers studying cannflavins and related polyphenols [Black Dollar Magazine] [Ontario Centre of Innovation]. The differentiation rests on a proprietary library of polyphenols (the company refers to its discovery layer as the PolyKye platform) coupled with cGMP botanical extraction capacity in Woodburn, Oregon, where Canurta Naturals took over operations of the FSOil facility [Canurta.com]. Funding to date is reported by the company at more than $13 million in combined equity, convertible debt, and non-dilutive capital, with $3.22M of that described as non-dilutive [Canurta.com, 2025] [BioSpace]. The team is small but credentialed in plant biochemistry, with research staff including Eric Soubeyrand and Kelly Boddington, the latter a co-author of peer-reviewed work on bibenzyl synthesis in Cannabis sativa [Wiley Online Library, 2022] [ZoomInfo]. Over the next 12 to 18 months, the substantive milestones to watch are the opening of CNR-401 first-in-human ALS dosing, the outcome of the Pre-IND and Orphan Drug Application processes flagged on the company website, and any disclosure of a priced Series A to fund the clinical program [Canurta.com, 2025].
Data Accuracy: YELLOW -- Lead pipeline and capital figures are largely company-sourced; corroboration exists for founding year, founder identity, and select team members via Crunchbase, PitchBook, and LinkedIn.
Taxonomy Snapshot
| Axis | Value | |---| | Stage | Seed | | Business Model | B2B | | Industry / Vertical | Healthtech / Biotech | | Technology Type | Botanical drug discovery, AI-assisted screening | | Geography | North America (Canada HQ, US extraction facility) | | Growth Profile | Venture Scale | | Founding Team | Solo Founder | | Funding | ~$13M reported across equity, convertible debt, and non-dilutive |
Company Overview
PUBLIC
Canurta Therapeutics traces its origin to founder Akeem Gardner's earlier work in industrial hemp through a venture called Atlas365, which ultimately led him into a research collaboration with University of Guelph scientists studying the anti-inflammatory polyphenols present in Cannabis sativa [Ontario Centre of Innovation]. That collaboration formalized as Canurta Inc. in 2021, with a stated focus on "upcycling hemp biomass and waste material to develop therapeutics that can help people and animals with current and future chronic diseases" [Ontario Centre of Innovation]. The legal entity is headquartered in Brampton, Ontario, with research and operational extensions into Woodburn, Oregon through an affiliated entity, Canurta Naturals [Canurta.com] [Crunchbase].
Key milestones in the public record include the company's 2021 incorporation and seed financing reported at $5 million within roughly two years of launch [Black Dollar Magazine] [PitchBook]; participation in the Accelerator Centre program in Waterloo, Ontario, which is also listed as an institutional investor [Tracxn]; the November 2024 presentation at the Life Sciences Investor Forum [GlobeNewswire, 2024]; and the announced operational transition at the FSOil cGMP botanical extraction facility in Oregon, which expanded the group's North American extraction capacity [Canurta.com]. The company also self-reports submission of Pre-IND and Orphan Drug Applications in support of CNR-401 [Canurta.com, 2025].
F6S has ranked Canurta among its Top 10 Health and Wellness companies in Canada for 2024 and Top 5 among Small Molecule and Peptide companies, per the company's LinkedIn page [LinkedIn]. These are directory rankings rather than independent clinical or commercial validation, but they reflect visibility within the Canadian early-stage ecosystem.
Data Accuracy: GREEN -- Founding year, HQ, and founder confirmed across Crunchbase, PitchBook, and the Ontario Centre of Innovation.
Product and Technology
MIXED
Canurta's stated platform centers on novel polyphenols, with a particular emphasis on cannflavins A and B and related bibenzyl compounds derived from hemp biomass [Canurta.com] [PUBLIC]. The lead asset, CNR-401, is described by the company as a proprietary liquid botanical drug composed of ten active compounds, including cannflavin A, intended to relieve symptoms and slow disease progression in ALS and other neurodegenerative diseases [Canurta.com, 2025] [PUBLIC]. The company further reports that CNR-401 demonstrated blood-brain barrier penetration and a favorable safety profile in mouse toxicology studies, and that first-in-human trials are planned to begin in 2025 [Canurta.com, 2025] [PUBLIC]. These are pre-clinical, company-disclosed claims and have not, on the basis of the captured public sources, been independently published in a peer-reviewed venue specific to CNR-401.
The discovery layer, branded PolyKye, is described on the company website as an AI-assisted system for identifying novel bioactives and predicting synergy across multi-compound formulations, with the goal of guiding lead selection [Canurta.com] [PUBLIC]. Canurta also describes integration of blockchain into its physical supply chain for traceability that aligns with FDA expectations for botanical drugs [Canurta.com] [PUBLIC]. The specific model architectures, training datasets, and validation benchmarks behind PolyKye are not described in the public sources captured here, so the AI claims should be read as a discovery aid rather than a clinically validated predictive engine [MIXED].
On the manufacturing side, Canurta Naturals' takeover of operations at the FSOil facility in Woodburn, Oregon gives the group cGMP botanical extraction capacity in the United States, with the same core operational team continuing to serve existing customers [Canurta.com] [PUBLIC]. That vertical integration into extraction is unusual for a seed-stage therapeutics company and could reduce CMC (chemistry, manufacturing, and controls) risk for an investigational botanical drug, though it also implies operating overhead that pure pre-clinical biotechs typically avoid.
Data Accuracy: YELLOW -- Pipeline and platform descriptions are sourced primarily to the company website; manufacturing footprint corroborated by company press release.
Market Research and Opportunity
PUBLIC
ALS remains one of the most underserved indications in neurology, with limited approved therapies and a patient population willing to enroll in early-stage trials. Canurta's positioning sits at the intersection of two larger and well-funded categories: neurodegenerative disease therapeutics and the FDA's botanical drug pathway codified in the 2016 Botanical Drug Development Guidance for Industry.
No third-party TAM/SAM/SOM figures specific to Canurta were captured in the cited research, so the sizing discussion here uses analogous public references. ALS itself is a small but high-value indication: the global ALS therapeutics market has been estimated by various commercial research firms in the low single-digit billions of US dollars annually, driven by the launches of Radicava (edaravone) and the now-withdrawn Relyvrio (sodium phenylbutyrate / taurursodiol). The broader neuroinflammation therapeutics opportunity is materially larger because it touches Alzheimer's, Parkinson's, multiple sclerosis, and chronic peripheral inflammatory conditions.
Demand drivers that are visible in the cited research include: a growing willingness of the FDA to engage with multi-component botanical drug submissions under the 2016 guidance; orphan drug incentives that Canurta has reportedly applied for [Canurta.com, 2025]; and a category-level pivot in pharma R&D toward multi-target therapies for complex diseases that single-molecule approaches have struggled to address [Canurta.com]. Adjacent markets that could absorb the platform's outputs include nutraceuticals (where botanical polyphenols already have commercial channels) and animal health (referenced in Canurta's earlier framing around treating animals as well as humans) [Ontario Centre of Innovation].
Regulatory and macro forces cut both ways. The botanical drug pathway is real but narrow: only a small number of botanical drugs (Veregen, Fulyzaq / Mytesi) have ever cleared FDA approval, which means the regulatory road is precedented but slow. Hemp-derived chemistry also carries scheduling and import considerations that pure synthetic small-molecule programs do not face.
| Market reference | Figure | Source type | |---| | Reported total capital raised by Canurta | ~$13M | Company-reported [Canurta.com, 2025] | | Reported non-dilutive component | $3.22M | Company-reported [Canurta.com, 2025] | | Reported seed round (2021) | $5M | Press [Black Dollar Magazine] |
Analyst takeaway: the table above shows what is actually verifiable in dollar terms today, which is the company's own capitalization rather than a third-party market sizing. For a seed-stage biotech, that is the more honest framing: the prize is option value on a successful ALS readout, not a near-term revenue TAM.
Data Accuracy: ORANGE -- No third-party Canurta-specific market sizing in the captured sources; figures shown are capitalization, not market size.
Competitive Landscape
MIXED
Canurta sits in a thinly populated niche of FDA-regulated botanical drug developers targeting neurological disease, which means its most relevant competitors are not direct one-for-one analogues but rather adjacent ALS programs and other multi-target botanical drug developers.
In ALS itself, the relevant incumbents and challengers include Mitsubishi Tanabe (Radicava / edaravone), Biogen (Qalsody / tofersen for SOD1-ALS), and a long tail of clinical-stage biotechs pursuing antisense, gene therapy, and small-molecule mechanisms. Among multi-component botanical drug developers that have engaged the FDA's botanical pathway, the precedent set by Napo Pharmaceuticals (Mytesi / crofelemer) and MediGene's earlier Veregen submission are the most relevant historical reference points; neither operates in ALS.
Where Canurta has a defensible edge today is in its vertical integration into cGMP botanical extraction through the Woodburn, Oregon facility, combined with a proprietary library of polyphenol chemistry that the company has built up since 2021 [Canurta.com]. CMC for botanical drugs is genuinely hard, and owning extraction infrastructure shortens the loop between formulation iteration and toxicology work. That edge is durable to the extent the underlying compound library and process know-how remain proprietary, but it is perishable if a larger neurology player decides to in-license cannflavin chemistry directly from academic groups.
Where Canurta is most exposed is on the clinical and capital fronts. A pre-clinical biotech entering first-in-human ALS trials in 2025 is competing for the same patient population, key opinion leaders, and trial site capacity as much better-capitalized programs. Biogen, for example, has a commercialized ALS drug, deep regulatory relationships, and a multi-asset neurology pipeline. Canurta's reported ~$13M total capitalization is meaningfully smaller than the typical Phase 1 budget for a CNS asset, which usually runs $15M to $40M to first interim readout, so a Series A or strategic partnership is a near-term financing requirement rather than an option [Canurta.com, 2025].
The most plausible 18-month competitive scenario: winner if Canurta's first-in-human CNR-401 cohort generates a clean safety signal and any signal of target engagement, which would likely attract a strategic partner in neurology or rare disease, validating the multi-target botanical thesis; loser if the trial is delayed past 2025 without a bridge financing announced, in which case the company's reported capitalization would face a real runway question against a category where peers are spending materially more.
Data Accuracy: ORANGE -- No named direct competitors in captured sources; competitive map drawn from public knowledge of ALS and botanical drug categories.
Opportunity
PUBLIC
If CNR-401 reads out cleanly in early human studies, Canurta has a credible path to becoming the first FDA-cleared multi-component botanical drug in neurodegeneration, which would open a category rather than just monetize a single asset.
The headline opportunity
The single largest outcome reachable from today's position is for Canurta to establish the multi-target botanical approach as a viable, repeatable drug development model in CNS, with CNR-401 as proof-of-concept and the PolyKye discovery layer as the engine that produces follow-on candidates. The cited evidence that makes this aspirational rather than fanciful: the company has reportedly submitted Pre-IND and Orphan Drug Applications [Canurta.com, 2025], owns cGMP extraction capacity in Oregon [Canurta.com], and has assembled plant-biochemistry research talent including peer-reviewed authors on cannabis polyphenol synthesis [Wiley Online Library, 2022]. None of those is a guarantee of approval, but together they describe a company that has done more of the unglamorous regulatory and CMC work than a typical seed-stage biotech.
Two or three growth scenarios
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Orphan-drug ALS path | CNR-401 receives Orphan Drug Designation and progresses through Phase 1 with a clean safety profile | FDA grant of orphan status and successful first-in-human dosing in 2025 | Pre-IND and Orphan Drug Applications reportedly submitted [Canurta.com, 2025]; pre-clinical BBB penetration data reported [Canurta.com] |
| Strategic partnership in neurology | A mid-cap neurology player in-licenses CNR-401 or takes an option on the PolyKye platform | Phase 1 interim safety readout in 2025-2026 | Capital constraint at ~$13M reported capitalization makes partnering the rational financing path [Canurta.com, 2025] |
| Adjacent commercial expansion via Naturals | Canurta Naturals' Oregon cGMP capacity generates near-term botanical extraction revenue from third-party customers, partially funding the therapeutics arm | Continued operation and expansion of the FSOil facility transition | Operational transition publicly announced with continuity of customers [Canurta.com] |
What compounding looks like
The flywheel, if it works, runs through the discovery platform: each additional polyphenol characterized, each formulation tested, and each piece of CMC know-how generated at the Oregon facility lowers the marginal cost and time to nominate the next botanical candidate. In a single-asset biotech, a clinical failure usually ends the company; in a platform biotech with a discovery engine and owned extraction capacity, a single clinical failure is more survivable because the next candidate is closer to IND-ready than it would be from a standing start. Evidence that this flywheel is starting includes the company's stated breadth beyond CNR-401 across its pipeline page [Canurta.com] and the academic publication record of associated researchers on broader cannabis polyphenol chemistry [Wiley Online Library, 2022].
The size of the win
Credible comparables in the rare neurology space include Amylyx Pharmaceuticals, which reached a multi-billion-dollar market capitalization at the peak of Relyvrio's commercial trajectory before subsequent Phase 3 setbacks, and Ionis / Biogen's Qalsody franchise. A single approved CNS asset with orphan exclusivity in ALS, even at modest peak sales, has historically supported enterprise values in the hundreds of millions to low billions of US dollars (scenario, not a forecast). Translating that to Canurta: a successful Phase 1 readout for CNR-401 would not by itself produce that outcome, but it would plausibly support a Series A at a step-up from current capitalization and put the company in the conversation for a partnership where the upside math starts to look like the comparable set above (scenario, not a forecast).
Data Accuracy: YELLOW -- Scenarios anchored to company-reported pipeline status and publicly known category comparables; outcomes are explicitly labelled as scenarios, not forecasts.
Sources
PUBLIC
[Canurta.com] Next Generation Botanical Drugs for Complex Diseases | https://www.canurta.com/
[Canurta.com] About Us | https://www.canurta.com/about-us
[Canurta.com] Next-Generation Botanical Pipeline | https://www.canurta.com/pipeline
[Canurta.com] Technology / Platform | https://www.canurta.com/platform
[Canurta.com, 2025] Investor Summary | https://www.canurta.com/investor-summary-1
[Canurta.com] Canurta Naturals to Lead Operational Transition at FSOil Facility | https://www.canurta.com/post/canurta-naturals-to-lead-operational-transition-at-fsoil-facility-expanding-cgmp-botanical-extracti
[Black Dollar Magazine] Canurta founder and CEO Akeem Gardner wants to bring a hemp processing facility to southern Ontario | https://www.blackdollarmag.com/canurta-founder-akeem-gardner-discovering/
[Ontario Centre of Innovation] Canurta: Exploring the anti-inflammatory benefits of hemp with CEO Akeem Gardner | https://www.oc-innovation.ca/success-stories/canurta-exploring-the-anti-inflammatory-benefits-of-hemp-with-ceo-akeem-gardner/
[LinkedIn] Canurta Therapeutics company page | https://ca.linkedin.com/company/canurta
[LinkedIn] Akeem Gardner profile | https://www.linkedin.com/in/akeemgardner/
[PitchBook] Canurta Therapeutics 2025 Company Profile | https://pitchbook.com/profiles/company/503587-81
[Crunchbase] Canurta Therapeutics company profile | https://www.crunchbase.com/organization/canurta-therapeutics
[Crunchbase] Akeem Gardner person profile | https://www.crunchbase.com/person/akeem-gardner
[Tracxn] Canurta 2025 Company Profile & Funding | https://tracxn.com/d/companies/canurta/__1qXf-MdPAzG-_R6cotcJP_GN7g2XliTS7933r5elhUY
[Wiley Online Library, 2022] Bibenzyl synthesis in Cannabis sativa L. | https://onlinelibrary.wiley.com/
[GlobeNewswire, 2024] Life Sciences Investor Forum presentation announcement | https://www.globenewswire.com/
[CanadianSME Small Business Magazine] Akeem Gardner on Breaking Barriers in Biotech & Bitcoin | https://canadiansme.ca/akeem-gardner-on-breaking-barriers-in-biotech-bitcoin/
Articles about Canurta Therapeutics
- Canurta Therapeutics Is Pushing a Hemp-Derived Drug Into First-in-Human ALS Trials — The Brampton biotech has raised more than $13M behind CNR-401, a 10-compound botanical candidate aimed at slowing neurodegeneration.